P/E ratio for BeiGene (BGNE)
P/E ratio as of April 2024 (TTM): -9.22
According to BeiGene 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.21995. At the end of 2022 the company had a P/E ratio of -11.4.
P/E ratio history for BeiGene from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -11.4 | -36.25% |
| 2021 | -17.8 | 31% |
| 2020 | -13.6 | 29.03% |
| 2019 | -10.5 | -10.14% |
| 2018 | -11.7 | -72.27% |
| 2017 | -42.3 | 412.24% |
| 2016 | -8.26 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -49.39% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -89.20% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.